Abstract
Globally, there are approximately 7.4 million cancer deaths annually, approximately 13% of deaths from all causes. Cancer is a disease of older people and, as the population ages over the next 10–20 years, we can expect an increase in the cancer incidence. Encouragingly, cancer mortality has stabilized in many countries. Part of this success may be attributed to the development of new cancer agents, collectively called ‘targeted therapies’, that are more specific to key components of tumour growth. Worldwide, however, one of the main factors that limit patient access to these important new drugs is their cost, which is higher than traditional chemotherapy. In this review, the clinical and pharmacoeconomic data of selected targeted agents are discussed. In the second part of this article, the challenges faced by healthcare systems in making such drugs available to patients is reviewed. Current strategies used by many countries around the world to manage cancer drug budgets are presented, along with a proposed approach using pharmacoeconomic methodology that may increase patient access.
Similar content being viewed by others
References
WHO. Cancers: the problem [NMH fact sheet]. Geneva: WHO, 2008 Jan [online]. Available from URL: http://www.who.int/nmh/publications/fact_sheet_cancers_en.pdf [Accessed 2010 Jan 18]
Kinsella K, Phillips DR. Global aging: the challenge of success. Popul Bull 2005; 60 (1) [online]. Available from URL: http://www.prb.org/Publications/PopulationBulletins/2005/GlobalAgingTheChallengeofSuccessPDF575KB.aspx [Accessed 2009 Dec 22]
National Cancer Institute. Surveillance Epidemiology and End Results (SEER). Washington, DC: National Cancer Institute, 2010 [online]. Available from URL: http://seer.cancer.gov/ [Accessed 2010 Jan 2]
Canadian Cancer Society. Canadian cancer statistics 2009. Toronto (ON): Canadian Cancer Society, 2009 [online]. Available from URL: http://www.cancer.ca [Accessed 2010 Jan 21]
Schiller JH, Harrington D, Belani CP, et al., Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8
Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009; 14: 478–88
Mahalingam D, Mita A, Mita MM, et al. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices and future development. Curr Probl Cancer 2009; 33: 73–111
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57
Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317–9
O’Dowd A. Watchdog set to reject four drugs for kidney cancer on the NHS [abstract]. BMJ 2008; 337: a1262
Cvetković RS, Perry CM. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2006; 66: 791–820
Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl. 2007 Jan; (67): 5–14
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–42
Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 4117–26
Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health 2005; 8: 462–70
Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig 2008; 28 (1): 55–65
Deconinck E, Miadi-Fargier H, Pen CL, et al. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics 2010; 28 (1): 35–46
Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007; 67 (2): 299–320
Siddiqui MA, Scott LJ. Imatinib: a review of its use in the management of gastrointestinal stromal tumors. Drugs 2007; 67 (5): 805–20
Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626–32
Cohen MH, Dagher R, Griebel DJ, et al. US Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 2002; 7: 393–400
Dalziel K, Round A, Stein K, et al. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004; 8: 1–120
Mabasa VH, Taylor SC, Chu CC, et al. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). J Oncol Pharm Pract 2008; 14: 105–12
Huse DM, von Mehren M, Lenhart G, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors. Clin Drug Investig 2007; 27: 85–93
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–26
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 Oct 20; 353 (16): 1673–84
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72
Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29–36
Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA trial. Value Health. Epub 2009 Mar 10
Chan AL, Leung HW, Lu CL, et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother 2009; 43: 296–303
McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 2008; 26 (8): 699–719
Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007; 67: 2045–75
Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008; 28: 23S–30S
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539–44
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–76
Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5422–8
Sandler AS, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006; 355: 2542–50
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–40
Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397–406
Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007; 43: 2487–94
Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 2007; 29: 2256–67
Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009; 20: 851–5
Ortega J, Vigil CE, Chodkiewicz C. Current progress in targeted therapy for colorectal cancer. Cancer Control 2010; 17: 7–15
Vincent MD. Optimizing the management of advanced non small cell lung cancer: a personal view. Current Oncol 2009: 219–31
Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408–17
Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308–24
Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009; 101: 1182–92
Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007; 11: 1–128
Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008; 11: 791–9
Wilking B, Jonsson N. A global comparison regarding patient access to cancer drugs. Ann Oncol 2007; 18 Suppl. 3: 1–77
Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199–205
Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013–9
Drummond MF, Mason AR. European perspective on the cost and cost effectiveness of cancer therapies. J Clin Oncol 2007; 25: 191–5
Wilking B, Jonsson N. A pan European comparison regarding patient access to cancer drugs. Stockholm: Karolinska Institute and Stockholm School of Economics, 2005
National Cancer Institute. Cancer trends progress report: 2007 update. Washington, DC: National Cancer Institute, 2007 [online]. Available from URL: http://progressreport.cancer.gov [Accessed 2010 Jan 18]
Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med 2009; 360: 626–33
Faden RR, Chalkidou K, Appleby J, et al. Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q 2009; 87: 789–819
Church S. UK’s NICE backs Pfizer’s Sutent and Celgene’s Revlimid. 2009 Feb 4 [online]. Available from URL: http://www.pharmastrategyblog.com/2009/02 [Accessed 2010 Jan 18]
Dranitsaris G, Leung PP. Using decision analysis modelling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy. Int J Tech Assessment Health Care 2004; 20: 289–95
Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473–81
Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st century cancer drug pricing. J Clin Oncol 2009; 27: 2111–3
Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines in generalized cost effectiveness analysis. Health Econ 2000; 9: 235–51
Sarin R. Criteria for deciding cost effectiveness for expensive new anticancer agents. J Cancer Ther 2008; 4: 1–2
Central Intelligence Agency. The world fact book 2009 [online]. Available from URL: http://www.cia.gov/library/publications/the-world-factbook/rankorder/2004rank.html [Accessed 2009 Nov 18]
Stark CG. The burden of cancer in Europe and the availability of cancer drugs. EJHP Practice 2009; 15: 20–3
Stovall S. Greece’s drug price cuts may spread, hitting pharma co profits. 2010 May 14 [online]. Available from URL: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=201005060849dowjonesdjonline000550 [Accessed 2010 Sep 2]
Spain announces big drug-price cuts, aiming for $1.6 billion savings. 2010 May 17 [online]. Available from URL: http://www.thepharmaletter.com/file/95032/spain-announces-bigdrug-price-cuts-aiming-for-16-billion-savings.html [Accessed 2010 May 17]
Germany cuts drug industry’s pricing power: the VFA Association of Research-based Pharmaceutical Makers criticize plan. 2010 May 25 [online]. Available from URL: http://www.chemanager-online.com/en/news-opinions/headlines/germany-cuts-drug-industrys-pricing-power [Accessed 2010 May 24]
Anand G. Prescribing caution: from Wall Street, a warning about cancer-drug prices: Morgan Stanley analyst creates stir in industry as he sees a backlash. 2010 Mar 15 [online]. Available from URL: http://www.consumerwatchdog.org/patients/articles/?storyId=16076 [Accessed 2010 Jan 18]
Hirschler B. NICE backs Iressa after Astra sets fixed cost. 2010 May 27 [online]. Available from URL: http://uk.reuters.com/article/idUKTRE64P70K20100527?loomia_ow=t0:s0:a54:g12:r5:c0.236844:b34316212:z3 [Accessed 2010 May 17]
de Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 2006; 7: 155–7
Towse A, Garrison Jr LP. Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010; 28 (2): 93–102
Acknowledgements
The authors are grateful to Kristine Dorward for her review and many helpful comments during the creation of this paper, and to the anonymous reviewers.
No sources of funding were used to prepare this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dranitsaris, G., Truter, I., Lubbe, M.S. et al. Advances in Cancer Therapeutics and Patient Access to New Drugs. Pharmacoeconomics 29, 213–224 (2011). https://doi.org/10.2165/11584210-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11584210-000000000-00000